FDA Inspection 1210490 — Ruben D. Kowalyszyn, MD
The FDA completed an inspection of Ruben D. Kowalyszyn, MD on Jul 14, 2023 in Viedma. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Jul 14, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Viedma (Argentina)
Additional details
Clinical Investigator (CI)